Cemiplimab
- Generic Name
- Cemiplimab
- Brand Names
- Libtayo
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1801342-60-8
- Unique Ingredient Identifier
- 6QVL057INT
- Background
Cemiplimab is a fully human monoclonal antibody that works against programmed death receptor-1 (PD-1), which is a negative regulator of T cell function. By blocking PD-1, cemiplimab works to enhance T cell-mediated antitumour responses.
Cemiplimab was first approved by the FDA on September 28, 2018, as the first FDA-approved treatment for advanced cutaneous squamous cell carcinoma (CSCC). It was later approved to be used in basal cell carcinoma and non-small non-small cell lung cancer. Cemiplimab was also approved by the European Commission on June 28, 2019. In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended cemiplimab be granted marketing authorization for the treatment of cervical cancer.
- Indication
Cemiplimab is indicated to treat:
- Associated Conditions
- Locally Advanced Basal Cell Carcinoma, Locally Advanced Cutaneous Squamous Cell Carcinoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Cervical Cancer, Metastatic Non-Small Cell Lung Cancer, Metastatic cutaneous squamous cell carcinoma, Recurrent Cervical Cancer, Metastatic Basal cell carcinoma
- Associated Therapies
- First Line Chemotherapy
Seven Biopharma Trends to Watch in 2025
75% of C-suite executives in life sciences are optimistic about 2025, citing growth and innovation. AI in biopharma is expanding, with increased investments and partnerships. Cancer vaccines and gene editing are advancing, with late-stage trials and new therapies. VC and IPO markets are rebounding, and M&A activity is expected to increase. Multiomics tools are expanding, and spatial biology is consolidating. Regulatory changes under Trump 2.0 may impact biopharma and health policy.
Related Clinical Trials:
Filling Unmet Needs in SCAC Is Key as Incidence Rates Are Rising
Incidence of squamous cell anal carcinoma (SCAC) is rising; ASCO's 2024 guideline recommends concurrent chemoradiation with mitomycin-C and 5-fluorouracil or capecitabine. Retifanlimab, a checkpoint inhibitor, showed improved progression-free survival and overall survival in phase 3 trials, potentially becoming a new standard of care for SCAC. SCAC, primarily HPV-driven, remains a significant unmet medical need with no FDA-approved treatments for advanced disease.
Related Clinical Trials:
Maia Biotechnology director Stan Smith acquires $46,800 in stock
Stan Smith, MAIA Biotechnology director, acquired 25,000 shares and warrants at $1.872 and $2.08 per share, respectively. MAIA's stock gained 139% in a year. The company expanded its Phase 2 trial, THIO-101, for third-line non-small cell lung cancer treatment, with promising interim results. MAIA considers an accelerated approval pathway based on trial outcomes.
Maia Biotechnology director Ramiro Guerrero buys $99998 in stock
Ramiro Guerrero, MAIA Biotechnology director, bought 53,418 shares at $1.872 each, totaling $99,998. MAIA expanded its Phase 2 THIO-101 trial for THIO with Regeneron's Libtayo® in third-line NSCLC. Interim results show 10.6-month median survival vs. 5.8 months for standard care.
PD-1 Non-Small Cell Lung Cancer Treatment Market 2034: EMA
DelveInsight's report on PD-1 Non-Small Cell Lung Cancer Market (2020-2034) highlights market growth, approvals, prevalence, therapies, and companies like Merck, Bristol-Myers Squibb, Genentech, and others. Key therapies include KEYTRUDA, OPDIVO, TECENTRIQ, and TIZVENI. Market drivers include premium-priced targeted agents and therapy expansion, while barriers include premium pricing of emerging therapies.
Regeneron's Odronextamab Shows Remarkable 100% Response Rate in Lymphoma
Odronextamab showed 100% complete response in untreated follicular lymphoma, 48% objective response in DLBCL post-CAR-T, and 77% complete response in relapsed/refractory marginal zone lymphoma. EU approval secured; U.S. resubmission planned for 2025.
Related Clinical Trials:
MAIA Biotechnology Announces Expansion of Clinical Supply Agreement with Regeneron
MAIA Biotechnology amends 2021 clinical supply agreement with Regeneron for THIO-101 Phase 2 trial expansion, aiming to assess THIO's efficacy in third-line non-small cell lung cancer patients resistant to previous treatments. New patient enrollment expected soon.
Related Clinical Trials:
MAIA Biotech expands phase 2 trial for lung cancer treatment
MAIA Biotechnology expands Phase 2 trial of THIO-101 to evaluate THIO in combination with Regeneron's Libtayo® for third-line NSCLC patients resistant to prior therapies. The trial aims to assess safety, tolerability, and efficacy, with interim results showing favorable survival rates and response rates. MAIA maintains strong liquidity and considers an accelerated approval pathway.
MAIA Biotechnology, Regeneron expand clinical supply agreement
MAIA Biotechnology amended its 2021 clinical supply agreement with Regeneron to expand the THIO-101 Phase 2 trial, assessing THIO with Libtayo for advanced NSCLC patients resistant to previous treatments. MAIA sponsors the trial, with Regeneron providing Libtayo, and expects to start enrolling new patients soon, potentially aiming for accelerated U.S. approval.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath